€38.50
1.85% day before yesterday
Xetra, Dec 27, 05:35 pm CET
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Sector
Industry

Dermapharm Stock price

€38.50
+1.55 4.19% 1M
+1.85 5.05% 6M
-3.84 9.07% YTD
-3.86 9.11% 1Y
-48.90 55.95% 3Y
-0.23 0.58% 5Y
+12.50 48.08% 10Y
Xetra, Closing price Fri, Dec 27 2024
+0.70 1.85%
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Sector
Industry

Key metrics

Market capitalization €2.07b
Enterprise Value €2.99b
P/E (TTM) P/E ratio 22.88
EV/FCF (TTM) EV/FCF 27.43
EV/Sales (TTM) EV/Sales 2.58
P/S ratio (TTM) P/S ratio 1.79
P/B ratio (TTM) P/B ratio 3.55
Dividend yield 2.29%
Last dividend (FY23) €0.88
Revenue growth (TTM) Revenue growth 0.16%
Revenue (TTM) Revenue €1.16b
EBIT (operating result TTM) EBIT €206.69m
Free Cash Flow (TTM) Free Cash Flow €108.81m
Cash position €118.57m
EPS (TTM) EPS €1.68
P/E forward 19.19
P/S forward 1.75
EV/Sales forward 2.52
Show more

Is Dermapharm a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Dermapharm Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Dermapharm forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Dermapharm forecast:

Buy
100%

Financial data from Dermapharm

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,159 1,159
0% 0%
100%
- Direct Costs 785 785
3% 3%
68%
374 374
5% 5%
32%
- Selling and Administrative Expenses 69 69
664% 664%
6%
- Research and Development Expense - -
-
-
306 306
21% 21%
26%
- Depreciation and Amortization 99 99
7% 7%
9%
EBIT (Operating Income) EBIT 207 207
26% 26%
18%
Net Profit 91 91
5% 5%
8%

In millions EUR.

Don't miss a Thing! We will send you all news about Dermapharm directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dermapharm Stock News

EQS
about one month ago
Im Segment „Andere Gesundheitsprodukte“ erzielt Dermapharm in den ersten neun Monaten 2024 einen Umsatz von 271,7 Mio. € (Vorjahreszeitraum: 287,9 Mio. €). Der Umsatzrückgang ist im Wesentlichen auf die französische Arkopharma zurückzuführen. Das erste Halbjahr 2023 war geprägt von außergewöhnlic...
AD HOC NEWS
about 2 months ago
Der Arzneimittelhersteller Dermapharm DE000A2GS5D8 kann weiter auf ein florierendes Geschäft mit Markenmedikamenten bauen.
AD HOC NEWS
about 2 months ago
Das Analysehaus Jefferies hat die Einstufung für Dermapharm DE000A2GS5D8 nach Zahlen auf "Buy" mit einem Kursziel von 49 Euro belassen.
More Dermapharm News

Company Profile

Dermapharm Holding SE engages in the development, manufacture. and market of patent-free pharmaceutical products. The company also involves in in-house development, in-house production, and distribution of pharmaceuticals and other healthcare products. It offers its products through the following brands: Dekristol 20,000 I.E., bite away, Herpotherm, sikapur, Ampho-Moronal, Solacutan, Ciclocutan, Minoxicutan, Prednisolut, Dienovel, Lactofem, Finapil, Panthenol-Augensalbe JENAPHARM, and Suxilep. The company was founded in 1991 and is headquartered in Grunwald, Germany.

Head office Germany
CEO Hans-Georg Feldmeier
Founded 1991
Website www.dermapharm.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today